Current status and future perspectives in HER2 positive advanced gastric cancer

• G. Roviello ^[1] ; M. Catalano ^[1] ; L. F. Iannone ^[3] ; L. Marano ^[2] ; M. Brugia ^[4] ; G. Rossi ^[4] ; G. Aprile ^[5] ; L. Antonuzzo ^[1]
  1. [1] University of Florence

     University of Florence

     Firenze, Italia

     
  2. [2] Università degli Studi di Siena

     Università degli Studi di Siena

     Siena, Italia

     
  3. [3] Department of Health Science, University “Magna Graecia” of Catanzaro, Catanzaro, Italy
  4. [4] Clinical Oncology Unit, Careggi University Hospital, Florence, Italy
  5. [5] Department of Oncology, San Bortolo General Hospital, AULSS8 Berica, Vicenza, Italy

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 6 (junio), 2022, págs. 981-996
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease. HER2 expression is the main biomarker to lead the addition of trastuzumab to first line systemic chemotherapy improving the overall survival in advanced HER2-positivegastric adenocarcinoma. The inevitable development of resistance to trastuzumab remains a great problem inasmuch several treatment strategies that have proven effective in breast cancer failed to show clinical benefit in advanced gastric cancer. In this review, we summarize the available data on the mechanisms underlying primary and secondary resistance toHER2-targeted therapy and current challenges in the treatment of HER2-positive advanced gastric cancer refractory to trastuzumab. Further, we describe the prognostic value of new non-invasive screening techniques, the current development of novel agents such us HER2 antibody–drug conjugates and bispecific antibodies, and the strategies with antitumor activity on going.